# US 2006/0154330 A1 · Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0154330 A1
- Document ID: US20060154330A1
- Status: Published application
- Kind: A1
- Application number: 10/526,768
- Filed: 2003-09-05
- Published: 2006-07-13
- Earliest claimed: 2002-09-06
- Assignees: Forschungsverbund Berlin E.V.
- Inventors: Enno Klussmann; Alexander Oksche; Walter Rosenthal
- Web page: https://patentgrep.com/patent/US20060154330A1

## CPC

- C07K 14/47: from mammals
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to a nucleic acid sequence encoding a protein kinase A anchor portein, to the use of said nucleic acid sequence in a fusion protein, to a method of determining the interaction of said protein kinase A anchor protein with regulatory subunits of protein kinase A, and to a method of identifying cell-permeable substances.

## Claims

### Claim 1

An isolated nucleic acid molecule selected from the group comprising:
a) a nucleic acid molecule comprising a nucleotide sequence according to SEQ ID No. 1,
b) a nucleic acid molecule comprising a nucleotide sequence having sufficient homology to be functionally analogous to a nucleotide sequence according to a),
c) a nucleic acid molecule which, as a consequence of the genetic code, is degenerated into a nucleotide sequence according to a) or b), and
d) a nucleic acid molecule according to a nucleotide sequence of a)-c), which is modified and functionally analogous to a nucleotide sequence according to a) through c) as a result of deletions, additions, substitutions, translocations, inversions and/or insertions.

### Claim 2 (depends on 1)

The nucleic acid molecule according to claim 1, characterized in that the nucleotide sequence specified under b) has at least 80%, preferably 90% homology to a nucleotide sequence as specified under a).

### Claim 3 (depends on 1)

The nucleic acid molecule according to claim 1, characterized in that said molecule is a genomic DNA, a cDNA and/or an RNA.

### Claim 4 (depends on 1)

A vector comprising a nucleic acid molecule according to claim 1.

### Claim 5 (depends on 4)

A host cell comprising the vector according to claim 4.

### Claim 6 (depends on 1)

A polypeptide encoded by a nucleic acid molecule according to claim 1.

### Claim 7 (depends on 1)

A recognition molecule directed against a nucleic acid molecule according to claim 1 or, a vector, or a host cell based thereon or a polypeptide encoded thereby.

### Claim 8 (depends on 7)

The recognition molecule according to claim 7, characterized in that said molecule is an antibody, an antibody fragment and/or an antisense construct, particularly an RNA interference molecule.

### Claim 9 (depends on 1)

A pharmaceutical composition, characterized in that said composition comprises a nucleic acid molecule according to claim 1, a vector or a host cell based thereon, a polypeptide encoded thereby or a recognition molecule corresponding thereto, optionally together with a pharmaceutically tolerable carrier.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A kit, characterized in that said kit comprises a nucleic acid molecule according to any of claims 1 to 3, a vector according to claim 4, a host cell according to claim 5, a polypeptide according to claim 6, a recognition molecule according to any of claims 7 or 8, optionally together with a pharmaceutically tolerable carrier, and/or the pharmaceutical composition according to claim 9.

### Claim 11 (depends on 1)

A method for the detection of an AKAP-PKA interaction, comprising the steps of:
a) providing (i) a first vector comprising a nucleic acid molecule according to claim 1 and a first marker, and (ii) a second vector comprising a second nucleic acid molecule which encodes a regulatory subunit of a protein kinase and a second marker,
b) incorporating the first and second markers in a cell, thereby transfecting the cell, and
c) performing a fluorescence resonance energy transfer (FRET) measurement, thereby detecting the AKAP-PKA interaction.

### Claim 12 (depends on 11)

The method according to claim 11, characterized in that interaction between AKAP and RIIα, RIIβ, RIα and/or RIβ is detected.

### Claim 13 (depends on 11)

The method according to claim 11, characterized in that an inhibitor of AKAP and/or a PKA is identified in such a way that the method is performed with and without addition of the inhibitor to be investigated, thereby providing an indication as to the inhibitor of AKAP and/or PKA.

### Claim 14 (depends on 11)

The method according to claim 11, characterized in that a membrane-permeable molecule is identified in such a way that a conjugate of the membrane-permeable molecule to be investigated and a membrane-permeable AKAP-PKA inhibitor is produced and AKAP-PKA interaction is detected with and without said conjugate or said molecule.

### Claim 15 (depends on 1)

Use of a nucleic acid molecule according to claim 1, a vector or a host cell based thereon, a polypeptide encoded thereby a recognition molecule corresponding thereto, a pharmaceutical composition based thereon, a kit based thereon or a method for the detection of an AKAP-PKA interaction or of an inhibitor of AKAP and/or PKA and/or of a membrane-permeable peptide.
